Our Services

Inflammation Disease Models

MD Biosciences Mode of Action Assays

MD Biosciences performs efficacy studies for proof-of-concept as well as assays for early screening and profiling of drug candidates. If there is a model or assay that you don't see listed, please contact a representative to discuss a custom assay design. 

 

Assay Name Species Category  
Senerga® Mode of Action    WP mouse in vivo
Antigen Presenting Cell Activation (APC) NA in vitro  
Antigen Presenting Cell Presentation NA in vitro  
T cell activation NA in vitro  
T cell proliferation NA in vitro
T cell cycle NA in vitro
T cell apoptosis NA in vitro
B cell activation NA in vitro  

  = whitepaper, WP

 

Senerga® Mode of Action Platform

An in vivo murine model that allows for the dissection of the various steps that constitue an adaptive immune response. By dissecting this pathway, the mode of action of a compound can be determined. The platform can also be adapted to answer many other fundamental questions surrounding immunomodulation.

Central to all immune responses are the interactions of such cells as dendritic cells (DCs), T cells and B cells. In particular, the CD4+ T cell is central to many inflammatory diseases such as asthma, arthritis, IBD, and MS. It therefore follows that if we can examine the effect of a compound on the CD4+ T cell and also on DC and B cells, then we are able to observe the critical interactions that underlie the disease process of a number of diseases. Since an effective immunomodulator may act at some point along the DC, T and B cell pathway, we observe the efficacy of a potential immunomodulator and are able to choose the target disease(s) based on mode of action. 

Custom assay designs are available. Please contact a representative to customize a Senerga Mode of Action Study for your requirements.